2025 North America Cancer Gene Therapy Market Revenue Opportunities Report
Description
The 2025 North America Cancer Gene Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North America Cancer Gene Therapy Market are Novartis International AG, Gilead Sciences Inc., Bristol-Myers Squibb (Celgene), and Bluebird Bio Inc. Novartis is a global pharmaceutical leader focusing on innovative cell and gene therapies, with significant investment in clinical research to develop novel cancer treatments. Gilead Sciences has expanded its presence after acquiring Kite Pharma, a pioneer in CAR-T cell therapy for cancer, solidifying its role in gene-modified cell therapies. Bristol-Myers Squibb, with its acquisition of Celgene, has a broad oncology portfolio incorporating gene therapies for various cancers. Bluebird Bio develops gene-based immunotherapies specifically aimed at cancer and rare genetic diseases, contributing to advancing cancer gene therapy in North America.
These companies leverage advanced technologies such as viral vector delivery, gene-induced immunotherapy, and gene editing to develop targeted cancer therapies. North America’s market leadership is driven by these biopharmaceutical giants through heavy research investments, collaborations with academic institutions, and streamlined regulatory pathways facilitated by the FDA. Their focus on personalized oncology treatments and immunotherapy positions them at the forefront of the growing market, which was valued at over USD 2 billion in 2024 and is expected to expand rapidly in the coming decade.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the North America Cancer Gene Therapy Market are Novartis International AG, Gilead Sciences Inc., Bristol-Myers Squibb (Celgene), and Bluebird Bio Inc. Novartis is a global pharmaceutical leader focusing on innovative cell and gene therapies, with significant investment in clinical research to develop novel cancer treatments. Gilead Sciences has expanded its presence after acquiring Kite Pharma, a pioneer in CAR-T cell therapy for cancer, solidifying its role in gene-modified cell therapies. Bristol-Myers Squibb, with its acquisition of Celgene, has a broad oncology portfolio incorporating gene therapies for various cancers. Bluebird Bio develops gene-based immunotherapies specifically aimed at cancer and rare genetic diseases, contributing to advancing cancer gene therapy in North America.
These companies leverage advanced technologies such as viral vector delivery, gene-induced immunotherapy, and gene editing to develop targeted cancer therapies. North America’s market leadership is driven by these biopharmaceutical giants through heavy research investments, collaborations with academic institutions, and streamlined regulatory pathways facilitated by the FDA. Their focus on personalized oncology treatments and immunotherapy positions them at the forefront of the growing market, which was valued at over USD 2 billion in 2024 and is expected to expand rapidly in the coming decade.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
